Hyperion DeFi, Inc. Common Stock (HYPD) Stock Price

HYPDStock

$3.41−47.08%52W

Market Cap$52.99M

P/E—

PEG Ratio—

Div yield—

Beta2.42

HYPD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-18.63%

Price vs S&P 500 (4W)31.66%

VGM Score51.67

Book Value / Share (Quarterly)$5.12

P/TBV (Annual)1.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-84.00%

Cash Flow / Share (Quarterly)$-7.57

Price vs S&P 500 (YTD)-20.39%

Gross Margin (TTM)70.93%

Net Profit Margin (TTM)-2329.74%

EPS (TTM)$-3.92

10-Day Avg Trading Volume0.57M

EPS Excl Extra (TTM)$-3.92

Revenue Growth (5Y)-16.47%

EPS (Annual)$-9.06

Dividend / Share (Annual)$0.18

ROI (Annual)-92.75%

Gross Margin (Annual)62.72%

Net Profit Margin (5Y Avg)-162564.62%

Cash / Share (Quarterly)$0.65

Revenue Growth QoQ (YoY)1559.44%

ROA (Last FY)-87.54%

Revenue Growth TTM (YoY)1455.11%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-153.50%

Operating Margin (TTM)-2335.54%

Cash Flow / Share (Annual)$-9.99

P/B Ratio0.74x

P/B Ratio (Quarterly)0.67x

Net Income / Employee (Annual)$-5,034,900

EV / Revenue (TTM)42.61x

Net Interest Coverage (TTM)-21.36x

ROA (TTM)-35.63%

EPS Incl Extra (Annual)$-9.06

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)1.76x

3-Month Avg Trading Volume0.51M

52-Week Price Return-47.08%

Revenue / Employee (TTM)$115,900

Tangible BV / Share (Quarterly)$3.72

P/S Ratio (Annual)53.29x

Asset Turnover (Annual)0.02x

52-Week High$15.00

Operating Margin (5Y Avg)-152377.62%

EPS Excl Extra (Annual)$-9.06

CapEx CAGR (5Y)207.90%

26-Week Price Return-7.39%

Quick Ratio (Annual)2.56x

13-Week Price Return-16.41%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)1.97x

Enterprise Value$44.45M

Revenue / Share Growth (5Y)11.36%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$90,400

Pretax Margin (Annual)-5570.58%

Cash / Share (Annual)$0.74

3-Month Return Std Dev90.55%

Gross Margin (5Y Avg)-1307.55%

Net Income / Employee (TTM)$-2,699,900

ROE (Last FY)-110.36%

Net Interest Coverage (Annual)-1.94x

EPS Basic Excl Extra (Annual)$-9.06

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-3.92

ROI (TTM)-37.53%

P/S Ratio (TTM)41.56x

Pretax Margin (5Y Avg)-162564.62%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$2.36

Forward P/E4.50x

Price vs S&P 500 (52W)-65.39%

Year-to-Date Return-8.43%

5-Day Price Return20.74%

EPS Normalized (Annual)$-9.06

ROA (5Y Avg)-334.23%

Net Profit Margin (Annual)-5570.58%

Month-to-Date Return23.48%

EBITD / Share (Annual)$-8.87

Operating Margin (Annual)-5456.49%

LT Debt / Equity (Annual)0.19x

ROI (5Y Avg)-97.89%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-3.92

P/TBV (Quarterly)0.93x

P/B Ratio (Annual)0.71x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-2329.74%

Book Value / Share (Annual)$4.73

Price vs S&P 500 (13W)-19.20%

Beta2.42x

Revenue / Share (TTM)$0.08

ROE (TTM)-42.80%

52-Week Low$2.34

vGradeC

gGradeB

mGradeC

vgmGradeC

HYPD Earnings Surprise History

Q3 250.05est. —

Q4 25-6.29est. -4.62

Q2 260.92est. 2.24

HYPD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
HYPDHyperion DeFi, Inc. Common Stock	C	B	C	$3.41
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Hyperion DeFi, Inc. Common Stock

Eyenovia is a clinical-stage ophthalmic company developing novel treatments using its proprietary microarray print (MAP) platform and Optejet delivery system—a precision-targeted alternative to conventional eye droppers. The company's pipeline aims to improve drug safety, tolerability, patient compliance, and therapeutic efficacy across multiple eye disease indications. Eyenovia's smart ophthalmic therapies leverage novel formulations and drug combinations powered by its targeted delivery technology.